Results 301 to 310 of about 412,622 (340)

Sulforaphane induces cell morphology change and cell apoptosis by activating endoplasmic reticulum stress in glioblastoma. [PDF]

BMC Cancer
Li N, Jiang Y, Wang A, Jiang T, Dai H, Xia C, Jiang T.   +6 more
europepmc   +1 more source

Research progress on the use of the optical coherence tomography system for the diagnosis and treatment of central nervous system tumors

Ibrain, Volume 11, Issue 1, Page 3-18, Spring 2025.
With the advantages of high‐resolution imaging, efficient image acquisition, intraoperative real‐time detection, and radiation‐free and noninvasive characteristics, optical coherence tomography (OCT) provides accurate diagnosis and effective intraoperative guidance for the minimally invasive diagnosis and treatment of central nervous system (CNS ...
Jiuhong Li, Ziba Ayi, Gonggong Lu, Haibo Rao, Feilong Yang, Jing Li, Jiachen Sun, Junlin Lu, Xulin Hu, Si Zhang, Xuhui Hui   +10 more
wiley   +1 more source

TRIM21 functions as an oncogene in glioblastoma by transactivating FOSL1 and promoting the ubiquitination of p27. [PDF]

Cell Commun Signal
Ramar V, Sidhu RS, Pako O, Cisse CR, Guo AA, Li J, Stapleton K, Guo S, Wang G, Liu M.   +9 more
europepmc   +1 more source

Immunomodulatory natural polysaccharide‐based nanoparticles for the treatment of neurodegenerative diseases

Ibrain, EarlyView.
Polysaccharide‐based nanoparticles offer versatile platforms for drug delivery and immune modulation in neurodegenerative diseases. This review highlights their potential in treating Alzheimer's, Parkinson's, and multiple sclerosis, focusing on targeted delivery and neuroinflammation.
Leto‐Aikaterini Tziveleka, Mariafrancesca Cascione, Paolo Pellegrino, Annalisa Bianco, Stefano Leporatti, Valeria De Matteis   +5 more
wiley   +1 more source

Machine learning-driven SLC prognostic signature for glioma: predicting survival and immunotherapy response. [PDF]

Front Pharmacol
Lin J, Yang X, Zhao K, Liu Y.
europepmc   +1 more source

Mechanisms of enhancer‐driven oncogene activation

International Journal of Cancer, EarlyView.
Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend, Ruud Delwel, Dorien Pastoors   +2 more
wiley   +1 more source

Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients. [PDF]

J Inflamm Res
Lu J, Zhang ZY, Zhong S, Deng D, Yang WZ, Wu SW, Cheng Y, Bai Y, Mou YG.   +8 more
europepmc   +1 more source

Development and validation of a nomogram for predicting cancer-related fatigue in patients with glioma: a multicenter study. [PDF]

Front Oncol
Wu Q, Su C, Xing M, Ouyang L.
europepmc   +1 more source

A novel cuproptosis-associated LncRNA model predicting prognostic and immunotherapy response for glioma. [PDF]

Discov Oncol
Lei B, Zhan A, You G, Wu H, Chen S, Zhang D, Liu Z, Zheng N.   +7 more
europepmc   +1 more source

Single-cell and spatial transcriptome analyses reveal MAZ(+) NPC-like clusters as key role contributing to glioma recurrence and drug resistance. [PDF]

J Transl Med
Gu Q, Wang K, Lu T, Xiao Y, Wu Y, Zhou H, Zhou K.   +6 more
europepmc   +1 more source